RAF1 and cancer: In Figure 1A, Hatzivassiliou and colleagues treated 19 cancer cell lines, comprising 4 BRAFV600E mutant lines, 7 RAF/RAS-WT lines, and 8 KRAS-MT lines, with varying concentrations of two RAF inhibitors and calculated the IC50 value for each drug in each cell line.